Preventive action of phentolamine on adrenaline induced blood glucose elevation in humans

1988 ◽  
Vol 117 (2) ◽  
pp. 166-172 ◽  
Author(s):  
S. Porta ◽  
H. M. H. Hofmann ◽  
U. Ertl ◽  
I. Rinner ◽  
P. Puerstner ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Human Subjects ◽  
Immunoreactive Insulin ◽  
Preventive Action ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Alpha Receptors ◽  
Adrenaline Infusion ◽  
Plasma Immunoreactive Insulin ◽  
Blood Glucose Elevation

Abstract. A comparison of the action of adrenaline infusion and a combined adrenaline + alpha blocker (phentolamine, Regitine®) infusion on blood glucose (BG), plasma immunoreactive insulin (IRI), BG/IRI ratio, C-peptide, and plasma cortisol levels was made in healthy young human subjects. The purpose of the experiment was to check, whether alpha block could abolish adrenaline-induced enhancement of blood glucose levels. The results show that during enhanced adrenaline levels, the use of regitine could indeed normalize blood glucose levels, not so much by increasing the IRI secretion, but by diminishing adrenalineinduced liver glycogenolysis via alpha receptors. This could be a model to prevent stress (adrenaline) induced metabolic deviations in diabetics, especially before and during predictable stress situations, e.g. examinations or surgery.

scholarly journals Peripherally administered KP-10 prevents development of insulin-induced hypoglycemic shock in diabetic rhesus monkeys

2019 ◽  
Vol 106 (4) ◽  
pp. 335-346
Author(s):  
IZ Qureshi ◽  
I Fatima
Keyword(s):  
Blood Glucose ◽  
Rhesus Monkeys ◽  
Therapeutic Potential ◽  
Saline Control ◽  
Insulin Administration ◽  
Preventive Action ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Respective Treatment ◽  
Blood Glucose Concentrations

Aim This study investigated whether kisspeptin-10 (KP-10) prevents diabetic rhesus monkeys from insulin-induced hypoglycemic shock. Materials and methods Thirty-six adult male rhesus monkeys were used, six in each group. Diabetes was induced with streptozotocin (45 mg/kg b.w.; single dose i.v.). Groups were as: saline control, insulin alone, pre-insulin (treated with KP-10, 30 min before insulin), post-insulin (treated with KP-10, 30 min after insulin), treated with premix dose of KP-10 (50 μg) and insulin, and the group treated with the kisspeptin antagonist P234 (50 μg). Following an overnight fast, each animal was subjected to respective treatment, and blood glucose concentrations were recorded every 30-min interval for 3 h. Results Intergroup comparisons demonstrated that treatment with KP-10 prior to insulin administration and kisspeptin–insulin premix treatment allowed blood glucose levels to rise to significantly higher levels (p < 0.001) by 180 min in diabetic and healthy animals compared to treatment with insulin alone. However, intragroup comparisons revealed a significant decrease in blood glucose level in diabetic animals only. Treatment with P234 antagonist followed by insulin administration abolished the preventive action of kisspeptin, whereby blood glucose decreased significantly (p < 0.001) in both diabetic and healthy animals. KP-10 post-insulin treatment, however, remained ineffective and led, instead, to significantly decreased glucose concentrations by 180 min in both diabetic and healthy animals when compared to animals treated with insulin alone. Conclusions KP-10 bears therapeutic potential to prevent hypoglycemic shock that may sometimes occur during intensive insulin therapy. Several pharmacological aspects of its interaction with insulin and other drugs, however, remain to be investigated.

scholarly journals VIRUS-INDUCED DIABETES MELLITUS

1973 ◽  
Vol 137 (5) ◽  
pp. 1226-1239 ◽  
Author(s):  
D. Wark Boucher ◽  
Abner Louis Notkins
Keyword(s):  
Blood Glucose ◽  
Encephalomyocarditis Virus ◽  
Immunoreactive Insulin ◽  
Free Access ◽  
Abnormal Glucose Tolerance ◽  
Male Mice ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Access To Food ◽  
Rapid Drop

Infection of DBA/2N male mice with encephalomyocarditis virus resulted in a diabeteslike syndrome characterized by hyperglycemia, glycosuria, hypoinsulinemia, polydipsia, and polyphagia. Blood glucose levels were elevated within 4 days after infection and reached a maximum mean level of 320 mg/100 ml within 12 days. Approximately 60–80% of the animals developed a transient hyperglycemia while 10–15% of the animals remained hyperglycemic for well over 6 mo. The remaining animals failed to become hyperglycemic but many had abnormal glucose tolerance curves. Hyperglycemia was most pronounced when animals were allowed free access to food, and the incidence of byperglycemia was related both to the strain and sex of the animals, with few females developing hyperglycemia. The amount of immunoreactive insulin in the plasma of infected hyperglycemic mice was significantly lower than in appropriate controls, and injection of exogenous insulin resulted in a rapid drop in the blood glucose levels. Despite the fact that certain animals were hyperglycemic for many months, virus could not be recovered from the pancreas after the first 10 days of the infection.

scholarly journals Emerging Applications for Intelligent Diabetes Management

AI Magazine ◽  
2012 ◽  
Vol 33 (2) ◽  
pp. 67 ◽  
Author(s):  
Cindy Marling ◽  
Matthew Wiley ◽  
Razvan Bunescu ◽  
Jay Shubrook ◽  
Frank Schwartz
Keyword(s):  
Decision Support ◽  
Blood Glucose ◽  
Diabetes Management ◽  
Health Care Cost ◽  
Blood Glucose Control ◽  
Support Vector ◽  
Preventive Action ◽  
Machine Learning Classification ◽  
Glucose Levels ◽  
Blood Glucose Levels

Diabetes management is a difficult task for patients, who must monitor and control their blood glucose levels in order to avoid serious diabetic complications. It is a difficult task for physicians, who must manually interpret large volumes of blood glucose data to tailor therapy to the needs of each patient. This paper describes three emerging applications that employ AI to ease this task: (1) case-based decision support for diabetes management; (2) machine learning classification of blood glucose plots; and (3) support vector regression for blood glucose prediction. The first application provides decision support by detecting blood glucose control problems and recommending therapeutic adjustments to correct them. The second provides an automated screen for excessive glycemic variability. The third aims to build a hypoglycemia predictor that could alert patients to dangerously low blood glucose levels in time to take preventive action. All are products of the 4 Diabetes Support SystemTM project, which uses AI to promote the health and wellbeing of people with type 1 diabetes. These emerging applications could potentially benefit 20 million patients who are at risk for devastating complications, thereby improving quality of life and reducing health care cost expenditures.

scholarly journals Pioglitazone Reverses Markers of Islet Beta-Cell De-Differentiation in db/db Mice While Modulating Expression of Genes Controlling Inflammation and Browning in White Adipose Tissue from Insulin-Resistant Mice and Humans

Biomedicines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 1189
Author(s):  
J. Jason Collier ◽  
Heidi M. Batdorf ◽  
Kaelan L. Merrifield ◽  
Thomas M. Martin ◽  
Ursula White ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Blood Glucose ◽  
White Adipose Tissue ◽  
Human Subjects ◽  
Metabolic Health ◽  
Whole Body ◽  
Carbohydrate Utilization ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Brown Adipose

Obesity, insulin resistance, and type 2 diabetes contribute to increased morbidity and mortality in humans. The db/db mouse is an important mouse model that displays many key features of the human disease. Herein, we used the drug pioglitazone, a thiazolidinedione with insulin-sensitizing properties, to investigate blood glucose levels, indicators of islet β-cell health and maturity, and gene expression in adipose tissue. Oral administration of pioglitazone lowered blood glucose levels in db/db mice with a corresponding increase in respiratory quotient, which indicates improved whole-body carbohydrate utilization. In addition, white adipose tissue from db/db mice and from humans treated with pioglitazone showed increased expression of glycerol kinase. Both db/db mice and humans given pioglitazone displayed increased expression of UCP-1, a marker typically associated with brown adipose tissue. Moreover, pancreatic β-cells from db/db mice treated with pioglitazone had greater expression of insulin and Nkx6.1 as well as reduced abundance of the de-differentiation marker Aldh1a3. Collectively, these findings indicate that four weeks of pioglitazone therapy improved overall metabolic health in db/db mice. Our data are consistent with published reports of human subjects administered pioglitazone and with analysis of human adipose tissue taken from subjects treated with pioglitazone. In conclusion, the current study provides evidence that pioglitazone restores key markers of metabolic health and also showcases the utility of the db/db mouse to understand mechanisms associated with human metabolic disease and interventions that provide therapeutic benefit.

scholarly journals Inhibitory Effect of Tangeretin and Cardamonin on Human Intestinal SGLT1 Activity In Vitro and Blood Glucose Levels in Mice In Vivo

Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3382
Author(s):  
Hideo Satsu ◽  
Ryosuke Shibata ◽  
Hiroto Suzuki ◽  
Shimon Kimura ◽  
Makoto Shimizu
Keyword(s):  
Blood Glucose ◽  
Inhibitory Effect ◽  
Postprandial Blood Glucose ◽  
Oral Glucose ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Blood Glucose Elevation ◽  
Lifestyle Related Diseases

Rapid postprandial blood glucose elevation can cause lifestyle-related diseases, such as type II diabetes. The absorption of food-derived glucose is primarily mediated by sodium/glucose cotransporter 1 (SGLT1). Moderate SGLT1 inhibition can help attenuate postprandial blood glucose elevation and prevent lifestyle-related diseases. In this study, we established a CHO cell line stably expressing human SGLT1 and examined the effects of phytochemicals on SGLT1 activity. Among the 50 phytochemicals assessed, tangeretin and cardamonin inhibited SGLT1 activity. Tangeretin and cardamonin did not affect the uptake of L-leucine, L-glutamate, and glycyl-sarcosine. Tangeretin, but not cardamonin, inhibited fructose uptake, suggesting that the inhibitory effect of tangeretin was specific to the monosaccharide transporter, whereas that of cardamonin was specific to SGLT1. Kinetic analysis suggested that the suppression of SGLT1 activity by tangeretin was associated with a reduction in Vmax and an increase in Km, whereas suppression by cardamonin was associated with a reduction in Vmax and no change in Km. Oral glucose tolerance tests in mice showed that tangeretin and cardamonin significantly suppressed the rapid increase in blood glucose levels. In conclusion, tangeretin and cardamonin were shown to inhibit SGLT1 activity in vitro and lower blood glucose level in vivo.

Provitamin A cassava hydrolysate with Lactobacillus rhamnosus GG regulates weight gain, lipids and postprandial glycemia in wistar rats and humans

2021 ◽  
Vol ahead-of-print (ahead-of-print) ◽  
Author(s):  
Modupeola Oguntoye ◽  
Olufunke Ezekiel ◽  
Olayinka Oridupa
Keyword(s):  
Weight Gain ◽  
Blood Glucose ◽  
Wistar Rats ◽  
Human Subjects ◽  
Lactobacillus Rhamnosus ◽  
Provitamin A ◽  
Oral Glucose ◽  
Content Type ◽  
Glucose Levels ◽  
Blood Glucose Levels

Purpose This study aims to evaluate the effect of probiotic provitamin A cassava hydrolysate with Lactobacillus rhamnosus GG (hLGG) on weight and lipid profile of Wistar rats and its glycemic index using Wistar rats and human subjects. Design/methodology/approach Adult male Wistar rats (n = 40, 120–150 g) were orally administered provitamin A cassava hydrolysate with 1 × 1010, 2 × 1010 and 4 × 1010 CFU/g encapsulated or CFU/mL free Lactobacillus rhamnosus GG for 30 days, during which weight and lipid profile of rats were monitored. Blood glucose levels of rats and human subjects were also measured in Oral Glucose Tolerance Test to determine the Glycemic indices of hLGG. Findings Rats administered the highest doses of free or encapsulated hLGG [(4 × 1010 CFU) (PHE4 and PHF4, respectively)] had the lowest (18.2 ± 0.7 and 8.0 ± 0.6%, respectively, p < 0.001) percentage body weight gain compared to control (40 ± 0.6%). Lowest cholesterol and triglyceride (42.4 ± 0.5 and 44.4 ± 0.7 g/dL, p < 0.001, respectively) were observed in rats administered PHE4, with the lowest plasma glucose concentrations in PHE4 and PHF4 groups (43 ± 1 and 49 ± 0.7 g/dL, p < 0.001, respectively). Oral Glucose Tolerance Test for rats and human subjects showed lower peak blood glucose levels and glycemic indices in hLGG groups compared to controls in a dose-dependent manner. Originality/value Consumption of soft drinks, which supply non-nutritive energy, may lead to degenerative metabolic disorders such as obesity and diabetes. Beverages with probiotics such as Lactobacillus rhamnosus GG, on the other hand, offer a positive weight management approach. Development of non-dairy beverages such as provitamin A cassava hLGG is ongoing. Provitamin A cassava hLGG showed its ability to control weight gain, blood glucose levels and serum lipids. Thus, the beverage can be consumed as a healthy alternative to soft drinks and for weight management.

Intraoperative Changes in Blood Glucose Levels Increase the Risk of Death in Cardiac Surgery

2006 ◽  
Vol 31 (03) ◽  
Author(s):  
H Hager ◽  
E Giorni ◽  
A Felli ◽  
B Mora ◽  
M Hiesmayr ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Blood Glucose ◽  
Glucose Levels ◽  
Risk Of Death ◽  
Blood Glucose Levels

ADRENERGIC CONTROL MECHANISM FOR ACTH SECRETION IN MAN

1973 ◽  
Vol 74 (2) ◽  
pp. 263-270 ◽  
Author(s):  
Yoshikatsu Nakai ◽  
Hiroo Imura ◽  
Teruya Yoshimi ◽  
Shigeru Matsukura
Keyword(s):  
Intravenous Infusion ◽  
Human Subjects ◽  
Blocking Agent ◽  
Inhibitory Effect ◽  
Plasma Acth ◽  
Acth Secretion ◽  
Glucose Levels ◽  
Alpha Receptors ◽  
Normal Human ◽  
Adrenergic Blocking

ABSTRACT In order to determine if an adrenergic mechanism is involved in the secretion of corticotrophin (ACTH), the effect of adrenergic-blocking or -stimulating agent on plasma ACTH, cortisol and glucose levels was studied in normal human subjects. The intravenous infusion of methoxamine, an alpha adrenergic-stimulating agent, caused a rise in plasma ACTH and cortisol. This increase in plasma ACTH and cortisol was significantly inhibited by the simultaneous administration of phentolamine, an alpha adrenergic-blocking agent, in combination with methoxamine. The intravenous infusion of propranolol, a beta adrenergic-blocking agent, caused no significant change in plasma ACTH and cortisol, although it enhanced the plasma ACTH response to insulin-induced hypoglycaemia. On the other hand, alpha adrenergicblockade by intravenous infusion of phentolamine significantly suppressed the plasma ACTH response to insulin-induced hypoglycaemia. These studies suggest a stimulatory effect of alpha receptors and a possible inhibitory effect of beta receptors on ACTH secretion in man.

Sign in / Sign up

Export Citation Format

Share Document